Cargando…
Anti-mitochondrial Antibodies in Patients with Dilated Cardiomyopathy
OBJECTIVE: It has been reported that anti-mitochondrial antibodies (AMAs) recognize mitochondrial antigens and are associated with some diseases involving multiple organs, such as primary biliary cholangitis, Sjögren syndrome, Hashimoto's thyroiditis, systemic sclerosis, interstitial pneumoniae...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Japanese Society of Internal Medicine
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7872813/ https://www.ncbi.nlm.nih.gov/pubmed/33456024 http://dx.doi.org/10.2169/internalmedicine.5422-20 |
_version_ | 1783649259409637376 |
---|---|
author | Yokokawa, Tetsuro Yoshihisa, Akiomi Misaka, Tomofumi Sato, Takamasa Kaneshiro, Takashi Oikawa, Masayoshi Kobayashi, Atsushi Yamaki, Takayoshi Kunii, Hiroyuki Takeishi, Yasuchika |
author_facet | Yokokawa, Tetsuro Yoshihisa, Akiomi Misaka, Tomofumi Sato, Takamasa Kaneshiro, Takashi Oikawa, Masayoshi Kobayashi, Atsushi Yamaki, Takayoshi Kunii, Hiroyuki Takeishi, Yasuchika |
author_sort | Yokokawa, Tetsuro |
collection | PubMed |
description | OBJECTIVE: It has been reported that anti-mitochondrial antibodies (AMAs) recognize mitochondrial antigens and are associated with some diseases involving multiple organs, such as primary biliary cholangitis, Sjögren syndrome, Hashimoto's thyroiditis, systemic sclerosis, interstitial pneumoniae, dilated cardiomyopathy, and tubulointerstitial nephritis. In the current study, we examined the prevalence of AMAs in patients with dilated cardiomyopathy (DCM) and their clinical characteristics. METHODS: We enrolled 270 patients with DCM. We measured serum AMAs and analyzed the associated factors. Out of the 270 patients, positive AMAs were detected in 3 patients (1.1%; mean age, 68 years old; 2 men). These three patients had a significantly higher prevalence of primary biliary cholangitis and myopathy and levels of alanine alkaline phosphatase than those who were negative for said antibodies. There were no significant differences in the levels of B-type natriuretic peptide, aspartate transaminase, and left ventricular ejection fraction between these groups of patients. During the follow-up period, two of the three patients died due to respiratory failure. The other patient survived but experienced type II respiratory failure. CONCLUSION: The prevalence of AMAs in 270 DCM patients was only 1.1%, and these patients suffered from respiratory failure. |
format | Online Article Text |
id | pubmed-7872813 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | The Japanese Society of Internal Medicine |
record_format | MEDLINE/PubMed |
spelling | pubmed-78728132021-02-17 Anti-mitochondrial Antibodies in Patients with Dilated Cardiomyopathy Yokokawa, Tetsuro Yoshihisa, Akiomi Misaka, Tomofumi Sato, Takamasa Kaneshiro, Takashi Oikawa, Masayoshi Kobayashi, Atsushi Yamaki, Takayoshi Kunii, Hiroyuki Takeishi, Yasuchika Intern Med Original Article OBJECTIVE: It has been reported that anti-mitochondrial antibodies (AMAs) recognize mitochondrial antigens and are associated with some diseases involving multiple organs, such as primary biliary cholangitis, Sjögren syndrome, Hashimoto's thyroiditis, systemic sclerosis, interstitial pneumoniae, dilated cardiomyopathy, and tubulointerstitial nephritis. In the current study, we examined the prevalence of AMAs in patients with dilated cardiomyopathy (DCM) and their clinical characteristics. METHODS: We enrolled 270 patients with DCM. We measured serum AMAs and analyzed the associated factors. Out of the 270 patients, positive AMAs were detected in 3 patients (1.1%; mean age, 68 years old; 2 men). These three patients had a significantly higher prevalence of primary biliary cholangitis and myopathy and levels of alanine alkaline phosphatase than those who were negative for said antibodies. There were no significant differences in the levels of B-type natriuretic peptide, aspartate transaminase, and left ventricular ejection fraction between these groups of patients. During the follow-up period, two of the three patients died due to respiratory failure. The other patient survived but experienced type II respiratory failure. CONCLUSION: The prevalence of AMAs in 270 DCM patients was only 1.1%, and these patients suffered from respiratory failure. The Japanese Society of Internal Medicine 2021-01-15 2021-01-15 /pmc/articles/PMC7872813/ /pubmed/33456024 http://dx.doi.org/10.2169/internalmedicine.5422-20 Text en Copyright © 2021 by The Japanese Society of Internal Medicine https://creativecommons.org/licenses/by-nc-nd/4.0/ The Internal Medicine is an Open Access journal distributed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License. To view the details of this license, please visit (https://creativecommons.org/licenses/by-nc-nd/4.0/). |
spellingShingle | Original Article Yokokawa, Tetsuro Yoshihisa, Akiomi Misaka, Tomofumi Sato, Takamasa Kaneshiro, Takashi Oikawa, Masayoshi Kobayashi, Atsushi Yamaki, Takayoshi Kunii, Hiroyuki Takeishi, Yasuchika Anti-mitochondrial Antibodies in Patients with Dilated Cardiomyopathy |
title | Anti-mitochondrial Antibodies in Patients with Dilated Cardiomyopathy |
title_full | Anti-mitochondrial Antibodies in Patients with Dilated Cardiomyopathy |
title_fullStr | Anti-mitochondrial Antibodies in Patients with Dilated Cardiomyopathy |
title_full_unstemmed | Anti-mitochondrial Antibodies in Patients with Dilated Cardiomyopathy |
title_short | Anti-mitochondrial Antibodies in Patients with Dilated Cardiomyopathy |
title_sort | anti-mitochondrial antibodies in patients with dilated cardiomyopathy |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7872813/ https://www.ncbi.nlm.nih.gov/pubmed/33456024 http://dx.doi.org/10.2169/internalmedicine.5422-20 |
work_keys_str_mv | AT yokokawatetsuro antimitochondrialantibodiesinpatientswithdilatedcardiomyopathy AT yoshihisaakiomi antimitochondrialantibodiesinpatientswithdilatedcardiomyopathy AT misakatomofumi antimitochondrialantibodiesinpatientswithdilatedcardiomyopathy AT satotakamasa antimitochondrialantibodiesinpatientswithdilatedcardiomyopathy AT kaneshirotakashi antimitochondrialantibodiesinpatientswithdilatedcardiomyopathy AT oikawamasayoshi antimitochondrialantibodiesinpatientswithdilatedcardiomyopathy AT kobayashiatsushi antimitochondrialantibodiesinpatientswithdilatedcardiomyopathy AT yamakitakayoshi antimitochondrialantibodiesinpatientswithdilatedcardiomyopathy AT kuniihiroyuki antimitochondrialantibodiesinpatientswithdilatedcardiomyopathy AT takeishiyasuchika antimitochondrialantibodiesinpatientswithdilatedcardiomyopathy |